Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013822 | 0.85 | LOXL2 (0.45) | LTA4HMAOBNPBWR1CTSSCTSK | |
| SCHEMBL16012547 | 0.83 | MAPK1 (0.44) | LTA4HMAOBNPBWR1CTSSCTSK | |
| SCHEMBL16013976 | 0.82 | LOXL2 (0.43) | LTA4HMAOBNPBWR1CTSSCTSK | |
| SCHEMBL893388 | 0.82 | CASP1 (0.50) | LTA4HNPBWR1CASP1 | |
| SCHEMBL3718582 | 0.81 | LOXL2 (0.57) | LTA4HMAOBNPBWR1TOP1TAAR1 | |
| SCHEMBL3717904 | 0.81 | CASP1 (0.49) | LTA4HCASP1 | |
| SCHEMBL18233504 | 0.80 | CASP1 (0.43) | LTA4HMAOBNPBWR1TAAR1KIF11 | |
| SCHEMBL3725421 | 0.79 | DPP4 (0.50) | LTA4HMAOBNPBWR1CTSSCTSK | |
| Hydrochloric Acid SCHEMBL18224136 | 0.79 | MAOB (0.45) | LTA4HMAOBNPBWR1TAAR1KIF11 | |
| SCHEMBL16013548 | 0.79 | PIK3CA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409864-B2 | Sulfonamide TRPA1 receptor antagonists | ARIO PHARMA LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | ARIO PHARMA LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135617-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. IN LIQUIDATION (IT) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774919-A1 | Novel sulfonamide TRPA1 receptor antagonists | PHARMESTE S.R.L. IN LIQUIDAZIONE (IT) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | TRPA1, TRPV1, TRPV2 | LTA4H 423/4885MAOB 3798/4885NPBWR1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.